CT111 / Chantibody Therapeutics, Shanghai Cell Therapy Group - LARVOL DELTA

CT111, a novel trispecific PD-1 x CTLA-4 x VEGF single-domain antibody, synergistically targets exhausted T cells and promotes cooperative antitumor effects (AACR 2025) - "CT111 is a novel, potential first-in-class single-domain trispecific antibody that can simultaneously target PD-1 and CTLA-4 immune checkpoints on exhausted T cells, while also targeting VEGF-mediated tumor angiogenesis to overcome immune suppression synergistically within solid tumors."

Trispecific • Oncology • Solid Tumor • CTLA4 • IFNG

CT111, a PD-1 x CTLA-4 x VEGF trispecific antibody, demonstrates potent anti-tumor efficacy through synergistic immune checkpoint blockade and VEGF inhibition with cooperative avidity (SITC 2025) - "Potent anti-PD-1/anti-CTLA-4 synergy was observed with CT111 compared to AK104 in SEB-stimulated primary immune cells, as evidenced by high IL-2 secretion and T-cell proliferation across multiple human donors. Cooperative binding to VEGF in vitro significantly enhances avidity for PD-1 and CTLA-4, suggesting that tumor-secreted VEGF may amplify CT111 activity within the TME. These findings support clinical development of CT111 for treatment of solid tumors, particularly in anti-PD-1 resistance setting."

Checkpoint block • Checkpoint inhibition • Clinical • Trispecific • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD8 • CD80 • CTLA4 • PD-1 • PD-L1 • PD-L2